- ten23 health®, a Swiss CDMO, has released its 2023 Fairstainability Impact Report, outlining significant progress in sustainability goals.
- Results including reduction of carbon footprint intensity by 44% since 2021 and diverted 43% of waste from disposal in 2023.
- The company also reports commitment to gender equality, with 48% women employees and a certified “no gender pay gap”.
ten23 health, a Swiss contract development and manufacturing organization (CDMO), has announced the release of its 2023 Fairstainability Impact Report. The report outlines the company’s major progress on its sustainability goals, combining Sustainability and Fairness into “Fairstainability”.
The company’s mission is to drive positive change in the pharmaceutical and CDMO industry. The 2023 Fairstainability Impact Report transparently provides the current status of key parameters and progress towards achieving its sustainability goals.
Prof. Dr. Hanns-Christian Mahler, Chief Enablement Officer (CEO) at ten23 health, said, “We are incredibly proud to announce significant progress on our sustainability agenda with the release of our third Fairstainability Report. Patients, People and Planet are our central commitments, and sustainability is at the core of everything we do.”
The report highlights include a reduction in carbon footprint and net positive operations. ten23 health® has reduced its carbon footprint intensity (scope 1 and 2 GHG emissions/revenue) by 44% since 2021 and is expecting to meet its 50% reduction target one year earlier than planned. The company has also diverted 43% of waste from disposal in 2023, up from 34% in 2022.
The 2023 Fairstainability Report shows how committed ten23 health is to being open and responsible in its efforts to be fair and sustainable. The company regularly checks how it affects the environment and society. It aims to lead the way and bring about change in making pharmaceutical manufacturing sustainable.
Overview of outsourcing trends 
